Baylor Scott & White Liver Consultants of Texas

Una nueva medicina podría derretir la grasa

Una nueva terapia que podría revolucionar la forma en que se maneja la enfermedad del hígado graso.

James Trotter, MD, Medical Director, Transplant Hepatology at Baylor University Medical Center is one of the chief investigators of a new therapy that could revolutionize how fatty liver disease is managed. According to the American Liver Foundation, 60 million Americans are living with nonalcoholic steatohepatitis (NASH) which is a part of a group of conditions that lead to fat buildup in the liver, inflammation and fibrosis. Early results were just published in The Lancet, one of the highest ranked medicine journals in the world.

Reducing barriers to living donor transplantation

This pilot study aims to determine how living donor transplant candidates fare after transplant. Data collection began in abril 2018 and will continue over the next two years to provide people considering donating more detailed information about the long-term benefits and risks of living donation.

Baylor University Medical Center is one of 16 sites nationwide participating in a pilot study to determine how living donor transplant candidates fare after transplant, whether they actually donate or not. There are six liver transplant sites, including Baylor, and ten kidney programs participating in the study. The need for solid organ transplants is still growing but living donor transplants have actually declined from their peak in 2004. One of the major barriers to living organ donation is that long-term outcomes for donors are unclear. The Scientific Registry of Transplant Recipients (SRTR) has now launched the Living Donor Collective (LDC) to establish a living donor registry to study the long-term outcomes of living organ donation.

The goal of the project is to establish a living organ donor registry where all living donor candidates who are evaluated will be entered into a database. All aspects of their physical and psychosocial well-being will be tracked. The (LDC) will follow up approximately one year after the transplant surgery or a year after the decision not to donate. Donors and non-donors will be followed to monitor long-term outcomes of both groups. Ultimately, the research collected over the next two years will provide people considering donating more detailed information about the long-term benefits and risks of living donation.

In the wake of the opioid crisis, more donated organs are infected with the hepatitis C virus, and many are declined as a result. But a Tarrant County woman says she's proof that.

• La carga mundial de enfermedades hepáticas relacionadas con el alcohol tiene una tendencia al alza
• Tasa de mortalidad por enfermedad hepática crónica subestimada
• Sumeet Asrani, MD, discusses liver health
• Ask the Expert, Dr. Asrani discusses "What is liver disease"
• "Liver buddies" for life: Niece saves her aunt’s life through organ donation
• Liver transplant at Baylor Scott & White Health: Patient-centered care for the entire journey
• Hepatic encephalopathy with Dr. Trotter
• Felices para siempre: una pareja se casa después de un trasplante de hígado que le salvó la vida